PT - JOURNAL ARTICLE AU - Bossart, Simon AU - Daneluzzi, Cloé AU - Moor, Matthias B. AU - Hirzel, Cédric AU - Seyed Jafari, S. Morteza AU - Hunger, Robert E. AU - Sidler, Daniel TI - HPV Vaccination in immunosuppressed patients with established skin warts and non-melanoma skin cancer: A single-institutional cohort study AID - 10.1101/2023.06.16.23291486 DP - 2023 Jan 01 TA - medRxiv PG - 2023.06.16.23291486 4099 - http://medrxiv.org/content/early/2023/06/19/2023.06.16.23291486.short 4100 - http://medrxiv.org/content/early/2023/06/19/2023.06.16.23291486.full AB - Background cSCC (cutaneous squameous cell carcinom) and its precursors are a major cause of morbidity especially in immunosuppressed patients and are frequently associated with human papilloma virus (HPV) infections.Objective The purpose of this study is to investigate the therapeutically potential of alpha-HPV vaccination for immunosuppressed patients with established cSCC and its precursors.Methods In this retrospective study, all patients who received Gardasil-9®, a nonavalent HPV vaccine, as secondary prophylaxis were examined. Dermatologic interventions in both the pre- and post-vaccination periods were analyzed with zero-inflated poisson regression and a proportional intensity model for repeated events with consideration of the clinically relevant cofactors.Results The hazard ratio for major dermatologic interventions was 0.27 (CI 0.14-0.51, p <0.001) between pre- and post Gardasil-9® intervention. Gardasil-9® vaccination showed good efficacy in reducing major dermatologic interventions even after correction of relevant cofactors and national COVID-19 case loads during the observational period.Limitation The retrospective study design and the rather low number of patients may influence study results. Furthermore, analysis of HPV types and data collection on vaccine-specific HPV antibody measurements was not possible.Conclusion Alpha-HPV vaccination may potentially cause a significant decrease in dermatologic interventions in immunosuppressed patients with high skin tumor burden.Capsule summaryLittle is known about a possible immunizing effect of alpha-vaccines in immunosuppressed patients with high skin tumor burdenAlpha-HPV vaccination such as Gardasil-9® may potentially cause a significant decrease in dermatologic interventions in IS patients with high skin tumor burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Canton of Bern gave ethical approval for this work (ID 2017-01267)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw data are available from the corresponding author on request.